This medication is applied to provide supportive relief across two fundamentally different clinical contexts: chronic movement disorders and acute viral infections. It is commonly used to help manage the symptoms of Parkinson's disease, control movement problems that are a side effect of certain medications, and treat or prevent infection caused by the Influenza A virus.

Improved Motor Control and Symptom Relief

This medication is applied in the treatment of Parkinson's disease and related syndromes, providing symptomatic relief for core manifestations like rigidity, tremor, and slowness of movement. Its primary role is generally used for managing dyskinesia, which are uncontrollable, erratic movements experienced by patients, contributing to improved motor control and assisting with functional stability in daily activities.

“This supports patients during difficult episodes by easing distress and assists with maintaining functional stability.”

Additionally, Инспирон is commonly used to address involuntary motor symptoms, known as extrapyramidal reactions, that may arise as an unwanted effect of certain other necessary medications. This use assists with easing the burden of these disruptive, drug-induced movements, supporting patients who need to maintain their primary treatment regimens with greater physical comfort.

---

Acute Support Against Influenza A

The medication has an independent function in the domain of infectious disease, where it is utilized for the prevention (prophylaxis) and treatment of illness caused by the Influenza A virus. Its use may help lessen the severity or duration of acute viral symptoms, including fever and overall malaise, and provides symptomatic support during periods of acute infection.

---

Quick Fact: Relief for Involuntary Movements
Инспирон is considered relevant for managing levodopa-induced dyskinesia, a common challenge in long-term Parkinson's therapy, assisting with functional stability.

Regulatory References

1. NIH MedlinePlus Drug Information overview

The eligibility for using Инспирон (Amantadine) is strictly defined by regulatory authorities based on patient age, physiological function, and pre-existing medical conditions. The official regulatory documents determine who is eligible for treatment and who is absolutely prohibited from using the medicine.

Contraindicated and Restricted Populations

Classification	Population or Condition (Official Regulatory Status)
Contraindicated	Patients with known hypersensitivity to the drug. Individuals with End-Stage Renal Disease (ESRD), defined by a very low creatinine clearance (CrCl below 15 mL/min/1.73 m^2). Women who are breastfeeding. Pregnancy (contraindicated in some European labels) [Source: EMA, FDA].
Restricted/Conditional Use	Patients with mild to moderate renal impairment (requires dose modification). Individuals with a history of major psychotic disorder or suicidal ideation (should ordinarily not be treated). Patients with untreated angle-closure glaucoma. Older adults (ge 65 years) often require a lower initial dose due to likely reduced renal function [Source: FDA, NIH].

Age-Specific Eligibility

• Use is contraindicated in infants younger than 1 year of age [Source: NIH, FDA].
• The use for indications other than Influenza A (e.g., Parkinson's disease) is not established in the pediatric population [Source: NIH].

Connection to the overall eligibility profile: Regulatory agencies establish absolute prohibitions (contraindications) based primarily on severe renal dysfunction and reproductive status. For other populations, such as older adults and those with psychiatric conditions, use is deemed conditional, requiring careful assessment against the risks to define the appropriate boundaries for treatment.

Interactions with other medicines and products

Regulatory labeling documents define the interaction profile of Amantadine (Инспирон) through its effects on renal clearance, pharmacodynamic synergy, and restrictions related to its antiviral action.

Pharmacokinetic Interactions

Amantadine's renal clearance is reduced by co-administration with substances that alkalinize the urine, leading to increased plasma exposure and risk of accumulation. This interaction involves medicines such as Acetazolamide and Sodium Bicarbonate. Furthermore, drugs known to inhibit renal tubular secretion, including Amiloride and certain diuretic components like Triamterene/hydrochlorothiazide, are also documented to increase Amantadine serum concentrations.

Pharmacodynamic and Substance Interactions

Co-use with other anticholinergic drugs is documented to result in additive anticholinergic effects, which may require dose adjustment of the co-administered agent. Concomitant use with alcohol is not recommended due to an officially documented risk of additive Central Nervous System (CNS) effects, including dizziness and confusion. Specific regulatory guidance exists for combining Amantadine with QTc-prolonging agents, such as Thioridazine, due to a heightened risk of additive cardiac effects.

Administration Restrictions

Live Attenuated Influenza Vaccines (LAIV) are officially not recommended for co-administration. This restriction is documented because the antiviral action of Amantadine may interfere with the vaccine's replication, potentially reducing its efficacy. Timing separation rules are necessary to mitigate this interaction.

Selective Blockade of the Mineralocorticoid Receptor

Инспирон works by acting as a highly selective antagonist that physically blocks the mineralocorticoid receptor ( MR), preventing the hormone aldosterone from binding and initiating its biological signals. This targeted blockade modulates the effector arm of the RAAS (Renin-Angiotensin-Aldosterone System).

---

Electrolyte and Fluid Balance Modulation

Blocking the MR in the kidneys alters ion transport proteins, leading to decreased reabsorption of sodium ( Na^+) and water, while simultaneously reducing the excretion of potassium ( K^+). This mechanism produces a mild diuretic effect and alters renal handling of sodium and water, which leads to a reduction of total blood volume.

---

Structural Cardiovascular Protection

Beyond the renal effects, the drug's mechanism also inhibits MR-mediated signaling in the heart and blood vessels. This action suppresses processes that lead to inflammation and fibrosis (scar tissue formation), and inhibits signaling pathways associated with pathological remodeling of the cardiovascular structure. This action alters signaling pathways that influence cardiovascular structure.

Инспирон is administered strictly by the oral route, available as immediate-release (IR) capsules, tablets, syrup, and specialized extended-release (ER) forms.

---

Administration Protocol

Parameter	Standard Instruction
Route of Administration	Oral for all forms.
Standard Dosing Schedule	Initial dose for Parkinson's disease is typically 100 mg once daily, gradually increasing to 100 mg twice daily over the first week. The maximum allowed daily dose for IR forms is 400 mg. Doses must be titrated gradually, usually in weekly intervals.
Special Administration	Immediate-release forms may be taken with or without food. Extended-release tablets and capsules must be swallowed whole to preserve their controlled release profile and must not be crushed, chewed, or divided.
Population Adjustment	Dose adjustment is mandatory for patients with impaired kidney function; specific regimens are detailed based on calculated creatinine clearance. For older adults, a lower initial dose is generally recommended due to age-related reduced clearance.
Discontinuation Rule	Long-term therapy must not be stopped abruptly; the dose must be gradually reduced (tapered) over a period of one to two weeks.

---

Standard Procedural Structure

The usage protocol involves starting with a low dose, such as 100 mg daily, followed by gradual, weekly dose increases until the required maintenance level is achieved. This protocol is systematically altered by a required dose reduction for older adults and patients with renal impairment, reflecting the impact of patient physiology on drug clearance. All forms are administered orally, with the ER forms having a swallow whole requirement to maintain their structural integrity. Finally, treatment cessation for long-term use follows a controlled, gradual tapering schedule to minimize risk.

Research evidence / Overview of studies

Overview of Key Clinical Findings

Research has explored whether the treatment may affect a range of patient symptoms and clinical biomarkers across diverse populations. Studies have generally focused on short-term measures of effect, though some long-term safety and outcome data exist.

The initial randomized controlled trials (RCTs) evaluated whether the treatment affects the perceived speed of symptom relief. The primary research examined whether it reduces symptoms of X. Follow-up research has explored whether it may affect patient-reported outcomes, such as daily functioning and general well-being.

---

Specific Research Areas

Long-Term Use and Quality of Life

Longitudinal observational research has focused on the safety and potential impact of extended use. A correlation was found between long-term use and quality of life. The research did not establish a causal relationship. Studies have investigated whether the combination affects the overall disease burden. Some studies have explored whether an effect on symptom frequency may be observed. The evidence on long-term outcomes remains limited and ongoing research continues to monitor these effects.

Combination with Physical Therapy

Research has been conducted on the combination of the drug with physical therapy. The combined approach was assessed in terms of its potential effect on mobility scores and time to achieve a functional milestone. Studies have compared the effect on pain of the treatment versus compound Y.

Use in Sub-Populations

Elderly Populations and Renal Impairment

Studies have evaluated the drug's use in elderly populations. Research has also examined its effects in people with severe renal impairment. More research is needed to understand how the body processes the drug in people with pre-existing conditions. Research has included exploring the use of this treatment in individuals unresponsive to standard care.

Pregnancy and Breastfeeding

Data regarding the use of the drug during pregnancy are limited. Animal studies have not consistently identified risks, but studies in humans are limited and do not allow for definitive conclusions. Studies have not been conducted in breastfeeding individuals, and it is not yet clear whether the drug is excreted in human milk.

Common questions about Инспирон (FAQ)

Q: What is the main medical purpose of the drug Инспирон?

According to official product information, the medicine, whose active ingredient is Amantadine, has a dual therapeutic purpose. It is officially indicated for the treatment of Parkinson's disease. The medicine is also approved for the prophylaxis (prevention) and treatment of Influenza A virus infection.

Q: What potential interactions are described between Инспирон and over-the-counter medications?

Official documents state that certain over-the-counter medications can interact with the medicine. This includes products that may cause additive Central Nervous System (CNS) effects, such as increased dizziness or confusion. Additionally, medications that make the urine less acidic (alkalinize the urine), like sodium bicarbonate, are noted to interact with the drug.

Q: What types of food or drink are commonly cited as potentially interacting with Инспирон?

Regulatory documents note that co-use of alcohol is generally not recommended. This is because alcohol can result in additive Central Nervous System (CNS) effects. These effects may include an increase in dizziness or confusion while taking the medicine.

Q: Are there reported long-term safety concerns or side effects associated with taking Инспирон?

The official product labeling highlights a specific safety consideration related to the long-term use of the medicine. Official documents indicate that long-term treatment should not be stopped abruptly. Abrupt withdrawal or rapid dose reduction following long-term use has been associated with a potentially severe symptom complex resembling Neuroleptic Malignant Syndrome (NMS).

Q: Is the potential for kidney injury a known risk factor described in the drug documentation?

Official information indicates that the drug is primarily processed by the kidneys. Patients with pre-existing impaired kidney function face an elevated risk of drug accumulation and toxicity. It is also noted that the drug can increase serum creatinine levels, which may give a false impression of mild kidney impairment during routine testing.

Q: What is the typical time frame to see the full therapeutic effect of Инспирон?

Official product information regarding the drug’s use for involuntary body movements (dyskinesia) associated with Parkinson’s disease indicates a rapid effect. The medicine's effect in reducing involuntary body movements has been reported to begin within approximately 48 hours of starting treatment.

Q: Is Инспирон a medication that affects sexual function or libido?

Official labeling has documented changes in sexual function associated with the medicine. This includes both the potential for decreased sexual desire (libido decrease) and, conversely, increased sexual urges (as part of impulse control behaviors).

Q: What type of monitoring (tests) is typically needed while taking Инспирон? (e.g., blood tests for potassium/kidneys)

Official monitoring recommendations typically involve regular checks of renal function, often through creatinine tests, due to how the medicine is cleared from the body. Monitoring of mental status is also recommended to check for changes such as confusion or depression. Furthermore, monitoring of blood pressure for signs of orthostatic hypotension (dizziness upon standing) is generally recommended.

Q: Is it important to take Инспирон at the exact same time every day?

Official information recommends taking doses at evenly spaced times throughout the day and night. This practice is intended to help keep the amount of the medicine in the blood steady. Maintaining a constant concentration is described as beneficial for consistent systemic action.

Q: Does Инспирон interact with common pain relievers like NSAIDs?

Regulatory checks have found no documented interaction between this drug and commonly used non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen.

Q: What conditions, besides high blood pressure, is Инспирон used to manage?

The officially approved indications for this medication are the treatment of Parkinson's disease and the prophylaxis (prevention) and treatment of Influenza A virus infection.

Q: Can taking Инспирон cause fatigue or unusual tiredness?

Yes, fatigue and unusual tiredness or weakness are listed among the side effects reported in official documentation. These effects are classified among the commonly and less commonly reported adverse reactions to the medicine.

How to Store and Dispose of Amantadine (Инспирон)

Official regulatory guidelines define specific conditions for storing and discarding Amantadine to maintain product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not allow the product to freeze.
Protection	Keep away from excessive heat, moisture, and light. Must be dispensed in a tight, light-resistant container.
Child Safety	Store the medicine out of the sight and reach of children and use a child-resistant closure.

Disposal Instructions

Expired or unused Amantadine should be disposed of via a drug take-back program if available. If not, dispose of the medicine in the household trash by mixing it with an undesirable substance, such as used coffee grounds or dirt, and placing it in a sealed container. The product must not be discharged into drains or wastewater.